KURA ONCOLOGY, INC. Deferred Tax Assets, Goodwill and Intangible Assets
KURA ONCOLOGY, INC. (KURA) had Deferred Tax Assets, Goodwill and Intangible Assets of $594.00 thousand as of 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets · last filed 2020-02-25
- 2019-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $594.00K.
- 2018-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $642.00K.
- 2017-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $708.00K.
- 2016-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $982.00K.
| Period end | Deferred Tax Assets, Goodwill and Intangible Assets |
|---|---|
| 2019-12-31 | $594.00K 10-K · filed 2020-02-25 |
| 2018-12-31 | $642.00K 10-K · filed 2020-02-25 |
| 2017-12-31 | $708.00K 10-K · filed 2019-03-05 |
| 2016-12-31 | $982.00K 10-K · filed 2018-03-12 |
| 2015-12-31 | $999.00K 10-K · filed 2017-03-14 |
| 2014-12-31 | $732.00K 10-K · filed 2016-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |